Mineralys Therapeutics News

We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth

Yahoo Finance20:08

Mineralys Therapeutics(MLYS.US) Officer Sells US$1,500 in Common Stock

$Mineralys Therapeutics(MLYS.US)$ Officer Rodman David Malcom sold 100 shares of common stock on May 9, 2024 at an average price of $15 for a total value of $1,500.Source: Announcement What is stateme

Futu NewsMay 11 04:58

Mineralys Therapeutics: Strong Buy on Upcoming ADVANCE Trial Results and Robust Financial Health

TipRanksMay 10 17:17

Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)

TipRanksMay 9 23:10

Mineralys Therapeutics Q1 2024 GAAP EPS $(0.70) Misses $(0.67) Estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.67) by 4.48 percent. This is a 37.25 percent decrease over losses

BenzingaMay 9 19:16

Mineralys Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 19:12 · Announcements

Mineralys Therapeutics 1Q Loss $31.5M >MLYS

Mineralys Therapeutics 1Q Loss $31.5M >MLYS

Dow JonesMay 9 19:08

Mineralys Therapeutics Cash, Cash Equivalents and Investments Were $338.6M as of March 31 >MLYS

Mineralys Therapeutics Cash, Cash Equivalents and Investments Were $338.6M as of March 31 >MLYS

Dow JonesMay 9 19:08

Press Release: Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topl

Dow JonesMay 9 19:00

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD)

GlobeNewswireMay 6 20:00

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic

GlobeNewswireMay 2 20:00

Mineralys Therapeutics Board Member Announces Departure

TipRanksApr 4 20:12

Goldman Starts Mineralys at Buy, Cites Upcoming Drug Data

Seeking AlphaApr 3 02:37

QuidelOrtho Stock Falls 11% on Savanna PVP4+ Assay Update

Seeking AlphaApr 3 02:01

Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30

Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.

BenzingaApr 2 19:10

Mineralys Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 126.93% Goldman Sachs → $30 Initiates Coverage On → Buy 08/08/2023 179.88% Credit Suisse $38 →

BenzingaApr 2 19:10

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 22 22:51

Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Mineralys Therapeutics, Inc. (MLYS) and Addus Homecare (ADUS)

TipRanksMar 22 17:20

Buy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic Developments

TipRanksMar 22 17:18

Earnings Call Summary | Mineralys Therapeutics(MLYS.US) Q4 2023 Earnings Conference

The following is a summary of the Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript:Financial Performance:Mineralys ended 2023 with cash, cash equivalents and investments totaling $

Futu NewsMar 22 02:43 · Conference Call